Depleted uranium screening and testing

(a)

Identification and Testing Required

The Secretary of Defense shall carry out a program to identify individuals who, during active service in the Armed Forces, are or have been exposed to depleted uranium and to provide those individuals with bioassay testing and notification of the results of such testing. (b)

Depleted Uranium-Exposed Personnel Identification Methods

(1)

Procedures for identification of exposed members

The Secretary of each military department shall establish procedures to identify members of the Armed Forces under the Secretary’s jurisdiction who are, or may have been, exposed to depleted uranium. For such purpose, the Secretary shall identify units and members under paragraph (2) and shall accept self-identification reports by members under paragraph (3). (2)

Identification of units and personnel

The Secretary of each military department shall identify units, and personnel assigned to units, that have been, or could have been, exposed to depleted uranium, based upon information about known exposure events (as determined under subsection (c)). (3)

Self reporting

The Secretary of each military department shall accept a report by an individual, or a primary care provider for an individual, that the individual, while a member of the Armed Forces under the Secretary’s jurisdiction, was, or may have been, exposed to depleted uranium based upon service on active duty (or training duty or funeral honors duty) in a theater of operations where depleted uranium was used, including travel through such an area. The Secretary shall prescribe procedures for receiving such reports. Such a self-identification report submitted to the Secretary under this paragraph shall be treated by the Secretary as identification of the individual for purposes of this subsection. (4)

Treatment of individuals no longer on active duty

In carrying out this subsection, the Secretary of each military department shall ensure that individuals no longer on active duty (including members of the reserve components who have been released from active duty, members who have been retired, and members who have been separated from service) are treated, for identification purposes, in the same manner as individuals remaining on active duty. (c)

Exposure Events

(1)

Types of events

The Secretary of Defense shall identify depleted uranium exposure events for purposes of this section. The exposure events identified shall include the following: (A)

Direct exposures

An event in which an individual— (i)is struck by depleted uranium munitions or depleted uranium armor fragments; (ii)enters, or is present within 50 meters of, a vehicle or structure with possible depleted uranium residues; or (iii)breathes smoke from fires involving depleted uranium materials. (B)

Equipment handling exposures

An event in which an individual may inhale depleted uranium compound particulates as a result of the handling of equipment or wreckage that has been, or could have been, contaminated with depleted uranium. (C)

Other exposures

Other significant or incidental exposure events identified by the Secretary, including the performance of activities in the area of depleted uranium damaged vehicles or structures or the traveling through or residing in any such area. (2)

Limited retroactivity

In addition to exposure events described in paragraph (1) occurring on or after the date of the enactment of this Act, such events during the period between January 1, 2003, and the date of the enactment of this Act may be considered for purposes of this section, if reported during the 60-day period beginning on the date of the enactment of this Act. (d)

Health-Care Services Required

(1)

Bioassay procedure

Any individual identified under subsection (b) shall be provided a health screening test by the Secretary of Defense. Such test shall be carried out using a bioassay procedure developed by the Secretary of Defense in consultation with the Centers for Disease Control and Prevention. The same bioassay procedure shall be used for all individuals identified under subsection (b) and for all types of exposure or possible exposure identified under subsection (c). (2)

Time for test

(A)

Exposures after enactment

In the case of an exposure event described in subsection (c) that occurs on or after the date of the enactment of this Act, the bioassay under paragraph (1) shall be administered not later than 180 days after the date of the event, except that in the case of an individual with an exposure event described in subsection (c)(3), the bioassay under paragraph (1) shall be administered not later than 30 days after the end of the individual’s deployment in the theater of operations, but such individual may be provided the bioassay earlier upon the individual’s request. (B)

Exposures before enactment

In the case of an exposure event described in subsection (c) that occurs before the date of the enactment of this Act, the bioassay under paragraph (1) shall be administered not later than 180 days after the date of the reporting of the event under subsection (c)(2). (3)

Furnishing of results

The Secretary of Defense shall provide the results of any bioassay procedure under this subsection to the individual tested, and the primary care manager or primary care provider of that individual, not later than 30 days after the Secretary receives those results. (e)

Personnel Tracking

The Secretary of each military department shall establish procedures for collecting, tracking, and maintaining information on the health status of individuals tested under subsection (d) for the purpose of assessing any long-term health consequences of exposure to depleted uranium. (f)

Independent Review of Bioassay Types and Contamination Thresholds

The Director of the Centers for Disease Control and Prevention shall conduct an independent review of bioassay types and contamination thresholds for purposes of the testing under subsection (d). (g)

Treatment

Based on the results of the bioassay tests, the Secretary of the military department concerned shall provide appropriate treatment for any illness of an individual resulting from a depleted uranium contamination or exposure.